Net income for the 40 weeks ended October 5, 2008 was $17 million, or $0.66 per diluted share, compared to $19.5 million, or $0.67 per diluted share, in the same period of 2007. Total revenues for the 40-week period in 2008 were $130.9 million, compared to $128.2 million for the prior-year period. Total domestic same-store sales for the 40-week period in 2008 decreased 2.1%, compared to a 2.6% decrease for the same period of 2007.

Cheryl Bachelder, CEO of AFC, said: "We are satisfied with our solid earnings performance in the third quarter, despite the economic challenges our customers and our restaurant operators are facing in this environment. We made a conscious decision to invest in gaining market share in these slow economic times, making traffic retention our top priority."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

As of September 30, 2008, the Company had consolidated total assets of $480 million and stockholders' equity of $68.5 million. The Company's stock is traded on the NASDAQ Global Stock Market under the symbol "CZWI".

About Citizens Community Bancorp, Inc.

Citizens Community Bancorp, Inc., based in Eau Claire, Wisconsin, is the holding company for Citizens Community Federal, a federal savings association operating 20 full-service banking offices in Wisconsin, Minnesota and Michigan. Please visit us online at www.citizenscommunityfederal.net.

Except for historical information contained herein, the matters contained in this news release and other information in the Company's SEC filings, may express "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements that are other than statements of historical facts. The risks and uncertainties that may affect the operations, performance, development, growth projections and results of the Company's business include, but are not limited to, the growth of the economy, interest rate movements, timely development by the Company of technology enhancements for its products and operating systems, the impact of the Company to successfully integrate acquired companies, Congressional legislation, changes in regulatory or generally accepted accounting principles and similar matters. Readers are cautioned not to place undue reliance on forward-looking statements that are subject to influence by the named risk factors and unanticipated future events. Actual results, accordingly, may differ materially from management expectations.

Citizens Community does not undertake, and specifically disclaims, any obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect the occurrence of anticipated and unanticipated events or circumstances after the date of such statements.

SOURCE: Citizens Community Bancorp, Inc.

Citizens Community Bancorp 
John Zettler, 715-836-9994 x109 
Senior Vice President and Chief Financial Officer

To access the simultaneous webcast of the conference call (a replay of which will be available), please access the Company's Investor Relations web site at http://investor.anntaylor.com.

SOURCE AnnTaylor Stores Corporation

http://investor.anntaylor.com

Visit the following link to begin chatting with your fellow shareholders: http://www.stockwire.com/chat ---------------------------------------------------------- (OTCBB:CHKT) Chemokine Therapeutics Corp.

Chemokine Therapeutics Announces Three Posters Presented on Its Lead Compound, CTCE-9908, at the 2008 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Conference Tuesday October 28, 8:45 am ET

VANCOUVER, BRITISH COLUMBIA-Oct 28, 2008 - Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease recently announced that three posters were presented at the 20th European Organization for Research and Treatment of Cancer - National Cancer Institute - American Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics held in Geneva, Switzerland, October 21-24, 2008.

Profile for Chemokine Therapeutics Corp.

Chemokine Therapeutics Corp., a development-stage company, focuses on the development of peptide-based drugs for human diseases. The company focuses on the area of chemokines, small proteins that regulate various physiological functions primarily in relation to the immune system. Its drug candidates in human clinical trials include CTCE-9908, which is in phase II clinical trials for the treatment of metastasis and angiogenesis cancers; and CTCE-0214 that is in phase I clinical trials stage for hematological support, and for neutrophil, platelet, and stem cell mobilization. The company's other products comprise CTCE-0422, which is in preclinical development stage for wound healing; and CTCE-0...

Detailed Description...

LAST $0.08 USD ----------------------------------------------------------

About Stockwire: Stockwire is one of the largest communities for Micro Cap Investors. We are the only place on the internet to provide LIVE CHAT ROOMS for dedicated stocks.

We have also pioneering a new way to research companies before you invest them. It's called a Stockumentary. A Stockumentary is a documentary on a publicly traded company. Imagine a Dateline NBC segment, but on a publicly traded company. We are the first company to ever bring this type of quality research to investors in this format.

The Stockumentary has video interviews with management, product demos, video tours of office or factory, research reports, sec filings and much more. All of this is delivered to investors in high quality video, either by mail or email.

Stockwire.com is owned by Stockwire Research Group Inc. (SRGI) and is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies.

As detailed below, this publication accepts compensation from some of the companies from which it features. To the degrees listed herein, this Newsletter should not be regarded as an independent publication. All statements and expressions are the sole opinions of the editors and are subject to change without notice. A profile, description, or other mention of a company in the Newsletter is neither an offer nor solicitation to buy or sell any securities mentioned.

While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at www.sec.gov and/or the National Association of Securities Dealers ("NASD") at www.nasd.com. The NASD has published information on how to invest carefully at its web site.

Readers can review all public filings by companies at the SEC's EDGAR page. www.sec.gov/edgar.shtml

Stockwire.com is an independent electronic publication committed to providing our readers with factual information on selected publicly traded companies. Stockwire.com is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.

From time to time SRGI sells shares in the open market it receives as compensation for coverage of client companies. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, the editors do not view the sale of the shares as contradictory to any advice delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.

Moreover, as detailed below, this publication accepts compensation from third party consultants and/or companies which it features on Stockwire.com. To the degrees enumerated herein, this newsletter and website should not be regarded as an independent publication.

The editor, members of the editor's family, and/or entities with which the editor is affiliated aside from Stockwire Research Group Inc. (SRGI) itself, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed in the newsletter.

THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF THE EDITORS OF STOCKWIRE.COM.

We often accept restricted shares of company stock; by SEC regulations, restricted shares cannot be sold into the market for a period of at least one year from the time that the shares are issued. In such cases, we detail in the Disclaimer the specific term of any restrictions. We also receive compensation in the form of stock options, in which case we receive the right to buy shares of the stock of the company at issue, at a specified time and a specified price. In such circumstances, we specify on our Disclaimer the terms of the options received. On occasion, we also accept free-trading shares in a company that we cover. However, by policy we generally do not buy or sell any shares of a company's stock within three trading days after any such company's profile, commentary, or other company-specific information is disseminated on Stockwire.com Web site. In cases where we do trade within the three day window, our volume will never represent more than 5% of the daily volume, thereby minimizing any effect we could have on the potential price movement.

While our policies as detailed above are designed to minimize any impact upon our members of a conflict of interest between our company and our members, each member should be fully aware that such potential and actual conflicts of interest may well exist due to the compensation structure detailed herein. For this reason, and because the information contained on Stockwire.com is updated on a regular basis as circumstances change, each member is strongly encouraged to periodically review the Profile Compensation section at http://www.stockwire.com/disclaimer_profiles.htm .

CONTACT: The Stockwire Group Tel: +1 512 358 8440 e-mail: info@stockwire.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.